CN1626244A - Combination for treating skin disease - Google Patents
Combination for treating skin disease Download PDFInfo
- Publication number
- CN1626244A CN1626244A CN 200410058126 CN200410058126A CN1626244A CN 1626244 A CN1626244 A CN 1626244A CN 200410058126 CN200410058126 CN 200410058126 CN 200410058126 A CN200410058126 A CN 200410058126A CN 1626244 A CN1626244 A CN 1626244A
- Authority
- CN
- China
- Prior art keywords
- treatment
- group
- ethacridine
- medicine
- prescription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A composition for treating the dermatopathy caused by fungus is prepared from the antifungal medicine and rivanol. Its advantages are higher curative effect, short course of treatment and no recurrence.
Description
[affiliated technical field]
The present invention relates to a kind of compositions that is used to prepare treatment dermatosis medicine, relate in particular to the application of compositions in preparation treatment humans and animals external use medicine for treating dermatosis product of medicine ethacridine and antifungal agent.
[background technology]
Following principle is that professional involved in the present invention is known:
1. the ethacridine chemical name is an ethacridine lactate, in people doctor and animal medicine is skin and the mucosa Cidex-7 of using always, be characterized in to kill various malignant bacterias widely, harmless to organizing in the treatment concentration limit, though its antibacterial action is slower, this medicine can be adsorbed on mucosa and the wound surface securely and effect continued one day.And its pharmaceutically active strengthens when Organic substance exists.
2. in people doctor and veterinary clinic, the dermatosis due to the fungal infection all has antibacterial secondary infection to a certain degree at the skin lesion position, thereby inflammatory generation in various degree must be arranged.
According to data-gathering, what preparation treatment was paid attention to considering by the traditional method of dermopathic external used medicine due to the fungal infection is to the killing of fungus, but and to be added with the Cidex-7 thing of kill bacteria in its component less.After inflammation appears in the focus of fungus infection formation, increased the humidity of diseased region, formed the external environment of well staying in, growing and breeding for morbific fungus again owing to inflammatory exudation.
Fungus has certain repellence and self has very strong variability antifungal drug is known, uses the dermatosis many easily recurrences of antifungal agent treatment by fungal infection merely.
" all treatments of dermatomycosis should continue medication 2-4 week behind the clinical cure or after the fungal culture feminine gender.Treatment generally need 1-3 month [see " and Han Qian etc. translate for Merck veterinary's handbook, (U.S.) Fu Leisa work, Beijing, the China Agricultyre University Press, 1997 the 4th edition, 637 pages].
[summary of the invention]
The inventor through repeatedly, for a long time clinical experiment and practice is found and proof: add skin antiseptic and disinfectant drug ethacridine at preparation treatment humans and animals in by the dermatosis medicine due to the fungal infection, be about to antifungal agent and these two components of ethacridine and share and can obviously increase curative effect, shorten the course of treatment and reduce relapse rate.
Antifungal agent of the present invention refers to indicate that the range of application of medicine with antifungic action and preparation comprises that treatment animal and human class is by the dermopathic medicine due to the fungal infection in people's Canon Medicine and veterinary drug pharmacopeia.
Compositions involved in the present invention can be used one or more antifungal agent as required in its mixture.
When ethacridine cooperates at the antifungal agent more weak with not having kill bacteria function or this function, can in compositions, suitably strengthen the content of ethacridine, the highest 3 ‰ (g/ml) that account for the formulation components total.Can appropriateness its content be decreased to 1 ‰ (g/ml) with antifungal agent (as econazole) with stronger antibacterial ability extremely.
Ethacridine cooperates antifungal agent to make preparation can comprise other active component, this component can be permeability such as dimethyl sulfoxide and the azone etc. that are used to increase medicine, skin cracking-off agent such as carbamide and have the salicylic acid that suppresses the fungus effect etc., antioxidant such as sodium metasulfite etc. concurrently.The professional who the present invention relates to about its components selection and consumption etc. when the invention process can specifically grasp according to the principle without prejudice to feature of the present invention as required.
When containing the medicine of compositions of the present invention, preparation can use all kinds of solvents, carrier and excipient to be mixed with the various dosage forms that adapt to percutaneous drug delivery as required.
Because ethacridine aqueous solution instability, especially under high light, can decompose, the interpolation organic solvent that can use simultaneously again after not making water as far as possible or using water dissolution so recommend to use organic solvent such as the glycerol that can keep its pharmaceutically active or propylene glycol when selecting primary solvent for use is as the propylene glycol or the glycerol of 50% (with the volumetric ratio of solution water).
For the ethacridine of avoiding and slow down in the preparation decomposes, goods should use black or brown packing material.
Because ethacridine makes liquid become breen after decomposing in aqueous solution, so in formulation products operation instruction involved in the present invention, should indicate when macroscopic variable color taking place and to use as this product.
The inventor is according to a large amount of evidences: compositions involved in the present invention is primary solvent with water and uses black or the pharmaceutical solutions of brown bottle packing preparation can be marked as 1 year with its effect duration, and uses glycerol or propylene glycol as primary solvent (comprise organic solvent account for the solvent total amount more than 50% the aqueous solution agent) use black or brown Packaging Bottle its effect duration can be marked as 3 years.
To the effect of ethacridine, whether dosage form such as cream, unguentum and Emulsion effect duration of containing preparation of compositions involved in the present invention all can be contained water and/or contain different component such as water according to components such as its solvent and excipient is decided its expiration date with reference to above-mentioned solvent.That is: water is that the preparation of solution or excipient etc. is 1 year, and it is that the preparation of solution or excipient is 3 years that organic solution and water add organic solvent, and packing is selected opaque materials for use.
[beneficial effect]
Compositions involved in the present invention is made or/and be used in and can significantly strengthen curative effect in the dermatological formulation due to the preparation treatment fungal infection, shorten the course of treatment and prevent recurrence effectively.
[specific embodiments]:
Mode by the following example further specifies the present invention, does not therefore limit the present invention among the described practical range.
1. clotrimazole and ethacridine are used:
Following prescription 1 is based on antifungal agent clotrimazole and ethacridine compositions, use dimethyl sulfoxide as one of solvent and the principal agent that promotes dermal osmosis, utilize carbamide as the dermatolysis agent, the main solvent propylene glycol has stronger permeability in addition, and this prescription is also preferable by the more serious dermatosis case result of use due to the fungal infection to humans and animals.
Prescription 1: for using clotrimazole liniment or spray (to call prescription 1 in the following text) outward:
Recipe ingredient:
Clotrimazole 10.0-20.0g
Ethacridine 1.0-3.0g
Salicylic acid 20.0-50.0g
95% ethanol 80.0-200.0ml
Carbamide 50.0-100.0g
Sodium pyrosulfite 2.0g
Dimethyl sulfoxide 400.0-500.0ml
Propylene glycol adds to 1000.0ml
Method for making:
In the prescription the variable of marking can be according to the state of an illness, age (age younger person's moderate reduction consumption but can not be lower than the minimum flow of marking), (the thicker person's appropriateness of skin increases the poultry species, otherwise then reduce) grasp of different factor appropriateness, earlier salicylic acid is added during preparation and fully be dissolved into salicylic acid alcohol solution in the ethanol, other medicines are mixed the back add above-mentioned salicylic acid alcohol solution, treat fully to mix and dissolving (but behind the container closure appropriate heating) back bottling, preparation is promptly finished in conventional sterilization, also can make spray.
Usage and dosage:
Pick in right amount and be applied to (or being sprayed in right amount) affected part, morning every day, evening are respectively once.
Clinical observation on the therapeutic effect:
Prescription 1 treatment people tinea pedis effect observation:
Tinea pedis claims beriberi and tinea pedis again, be human a kind of by due to the fungal infection so that blister to be arranged between toe, fester even the squama keratinization, the affected part play is itched and is the common skin diseases of principal character, re-use the antifungal agent treatment after some these diseases of data record treatment are advocated and used potassium permanganate or ethacridine class skin antiseptic and disinfectant drug and antibiotic with infection control earlier and (see that Wang Guang is superfine, the skin science, Beijing, People's Health Publisher's second edition in October nineteen ninety, 117 pages), the county healthcare hospital for women ﹠ children in inventor place county is according to the inventor's suggestion, the case of accepting for medical treatment in its outpatient service after October 2 calendar year 2001 is used above-mentioned prescription 1 treatment, and effect is remarkable.A group in the following table is the case statistics of this chief minister with prescription 1 treatment, and the B group is to use traditional therapy before October 1 calendar year 2001---promptly use the statistics of the related data of the antifungal agent treatment case that does not add ethacridine.
Table 1 uses prescription 1 treatment tinea pedis recovery from illness situation relatively
The group treatment example recovery from illness example routine cure rate (%) of not fully recovering
A organizes 138 136 2 98.6
B organizes 147 25 122 17.0
Add up to 285 161 124 56.5
1.A group compares with the B group, P＜0.01 illustrates that two groups have notable difference, and A group curative effect obviously is better than the B group.
2. whether each table of (notes) Ben Biao and presents and recurrence and recovery from illness related data standard are checked through former pathomycete for recovery from illness in the affected part after 60 days.
Table 2 uses prescription 1 treatment tinea pedis to compare the course of treatment
Group course of treatment (my god) average natural law
A organizes 394453 11 14 47 6.4
B organizes 9 22 18 10 40 7 23 11 35 15 19.0
From last table more as can be seen, A group obviously shortens than the B group course of treatment.
Table 3 uses prescription 1 treatment tinea pedis produce effects case recurrence situation statistics
Group produce effects example recurrence example (notes) does not recur routine relapse rate (%)
A organizes 138 2 136 1.4
B organizes 122 92 30 75.4
Add up to 260 94 166 36.2
The A group compares with the B group, and P＜0.01 illustrates that two groups have notable difference, and A group curative effect obviously is better than the B group.
Fill a prescription 2. clotrimazoles and ethacridine cream (with call in the following text the prescription 2):
Recipe ingredient:
Clotrimazole 10-30g
Ethacridine 1.0-3.0g
Salicylic acid 20.0-50.0g
Stearic acid 120.0g
Span 100.0ml
Vaseline 200g
Glycerol adds to 1000.0ml
Method for making:
All components mixes, and fully stirs, and grinds fully in the electronic mortar of packing into.
Usage and dosage:
Be coated with twice of every day outside the affected part.
Clinical observation on the therapeutic effect:
Use prescription 2 treatment people tinea cruris effect observations:
Tinea cruris is by multiple fungus-caused a kind of human common skin diseases such as trichophyton, often betide the fold place that groin links to each other with pudendum, sometimes can spread to scrotum or buttocks inter-drain, its skin lesion mainly with annular, how annular center disappears, peripheral expansion is characteristics, but how at skin lesion place microscopy to pathomycete.The traditional treatment way is external 3% clotrimazole cream and salicylate compound fine wine etc., and for skin lesion extensively and the patient that grows of the course of disease, polygamy closes griseofulvin for oral administration.But it is unsatisfactory to find to use the said method effect in clinical, some skin lesion are than the lighter, because the unsatisfactory curative effect of said medicine has certain proportion to transfer to chronic and more refractory treatment, Zhaozhou County healthcare hospital for women ﹠ children has received ideal effect according to the inventor's suggestion in prescription 2 treatments of using this description after 7 days January in 2002 in the case that it is accepted for medical treatment.
A group in the following table is the case of this chief minister with prescription 2 treatments, and the B group is to use traditional therapy before this---promptly do not add the antifungal agent treatment case of ethacridine.The statistical result of two groups of related datas is as follows:
Table 4 uses prescription 2 treatment tinea cruris curative effects relatively
Group treatment example recovery from illness example (notes) the routine cure rate (%) of not fully recovering
A organizes 50 48 2 96
B organizes 50 28 22 56
Add up to 100 76 24 76
The A group compares with the B group, routine p＜0.01 of fully recovering, and A group effect is remarkable.
Table 5 uses prescription 2 treatment tinea cruris drug treatments relatively
Each case of group course of treatment (my god) average natural law
A organizes 865678 10 13 10 6 7.9
B organizes 45 35 32 35 38 39 42 40 20 39 36.6
By last table more as can be seen, A group obviously shortens than the B group course of treatment.
Table 6 uses prescription 2 treatment tinea cruris recurrence situations relatively
Group produce effects example recurrence example (notes) does not recur routine relapse rate (%)
A organizes 50 2 48 4.0
B organizes 44 42 2 95.5
Add up to 94 44 50 46.8
The A group compares with the B group, P＜0.01, and A group effect is remarkable.
2. ketoconazole and ethacridine are used:
Prescription 3: the propylene glycol solution of ketoconazole and ethacridine (to call prescription 3 in the following text)
Recipe ingredient:
Ketoconazole 10.0-20.0g
Ethacridine 2.0g
White wax 10.0g
Hexadecanol 15.0ml
Sodium lauryl sulphate 5.0g
Propylene glycol adds to 1000.0ml
Method for making:
All components mixes, fully dissolving, bottling (or bag etc.) sterilization.
Usage and dosage:
Be applied to the affected part, twice of every day.
Clinical observation on the therapeutic effect:
Use prescription 3 treatment cat ringworm effects:
Cat ringworm 98% is a kind of common skin diseases that the dog pityrosporion ovale causes cat, its clinical symptoms with around ear, depilation or disconnected hair, affected part take place tangible tickle and itch is arranged be feature in position such as face.As aforesaid about the characteristics of fungus associated diseases, the ringworm of cat be a kind of course of disease long, be difficult to cure and a kind of refractory skin that relapse rate is very high.The inventor uses traditional method promptly to use clotrimazole not add ethacridine before in October, 2002 and treats this disease (being the case of B group in the following table), is after this using clotrimazole to add ethacridine treatment (being the case in the A group of following table).The statistical result of two groups of related datas is as follows:
Table 7 uses the ringworm curative effect of prescription 3 treatment cats to compare
Group treatment example recovery from illness example (notes) the routine cure rate (%) of not fully recovering
A organizes 38 37 1 97.37
B organizes 42 28 14 66.67
Add up to 80 65 15 81.25
The A group compares with the B group, p＜0.01, and effect is remarkable.
Table 8 uses the ringworm recurrence situation of prescription 3 treatment cats to compare
Group produce effects example recurrence example does not recur routine relapse rate (%)
A organizes 38 1 37 2.63
B organizes 35 14 21 40.00
Add up to 73 15 58 20.55
The A group compares with the B group, p＜0.01, and A group effect is remarkable.
Table 9 uses prescription 2 treatment tinea cruris drug treatments relatively
The group case course of treatment (d) is average
A organizes 4 14 99 10 4 16 21 993 9.82
B organizes 44 34 9 18 43 28 19 40 29 19 46 29.91
By last table more as can be seen, A group obviously shortens than the B group course of treatment.
3. nystatin and ethacridine are used:
Prescription 4: nystatin and ethacridine skin mucosa penetrating agent (to call prescription 4 in the following text)
Recipe ingredient:
Nystatin 15.0-20.0g
Ethacridine 1.0-3.0g
Azone 20.0ml
Glycerol adds to 1000.0ml
Method for making:
(can be heated to 50 ℃) fully mixed, dissolved to used component, bottling, sterilization.
Usage and dosage:
The clear water back of thoroughly gargling picks a little with cotton balls etc. and is coated with and puts the affected part on the skin after morning every day, noon, the supper.
Clinical observation on the therapeutic effect:
Use prescription 4 treatment people thrush effect observations:
Thrush be by due to the monilial infection oral mucosa in the fungus a kind of common surgery diseases, clinical with oral mucosa have the abnormal pigmentary deposit on the skin of festering, unusual pain and repeatedly outbreak be feature.Traditional therapy is sucked for the nystatin sheet.The inventor utilizes nystatin to add outside the ethacridine affected part and is coated with, and has received good curative effect.
The county healthcare hospital for women ﹠ children in inventor place county under the inventor's participation, instructing, in calendar year 2001 the December case that this gate is accepted for medical treatment in examining after 16 days use above-mentioned prescription 1 treatment, effect is remarkable.A in following table group is the case statistics of this chief minister with prescription 1 treatment, the B group be calendar year 2001 December used traditional therapy before 16 days---the antifungal agent treatment case that does not promptly add ethacridine is added up.The statistical result of two groups of related datas is as follows:
Table 10 uses prescription 4 treatment people thrush curative effects relatively
Group treatment example recovery from illness example (notes) the routine cure rate (%) of not fully recovering
A organizes 61 17 44 27.87
B organizes 55 4 51 7.27
Add up to 116 21 22 18.10
The A group compares p＜0.01 with the B group.
Table 11 uses prescription 4 treatment people thrush recurrence situations relatively
Group is treated routine produce effects example recurrence routine relapse rate (%)
A organizes 61 61 44 72.13
B organizes 60 58 56 96.55
Add up to 121 119 100 84.03
Find out that from last table prescription 4 does not use the method for ethacridine to make the relapse rate of people's thrush descend 24.42 percentage points more simultaneously.
Table 12 uses prescription 2 treatment thrush to fully recover the routine course of treatment relatively
The group case course of treatment (d) average (my god)
A organizes 5332243334 3.2
B organizes 11 889 11 10 15 97 15 10.3
By last table more as can be seen, A group obviously shortens than the B group course of treatment.
[optimum implementation]
Outside repeatedly facts have proved following confession, use ketoconazole and ethacridine liniment (or spray) prescription and good curative effect is all arranged for the case of various fungal infection, various degree.
Recipe ingredient:
Ketoconazole 10.0-30g
Ethacridine 1.0-2.0g
Salicylic acid 20.0-50.0g
95% ethanol 80.0-200.0ml
Carbamide 50.0-100g
Sodium pyrosulfite 2.0g
Dimethyl sulfoxide 400.0ml
Propylene glycol adds to 1000.0ml
Method for making:
Earlier salicylic acid is added and fully dissolve formation salicylic acid alcohol solution in the ethanol, other medicines are mixed the back add above-mentioned salicylic acid alcohol solution, preparation is promptly finished in conventional sterilization after bottling, and also can make spray.
Usage and dosage:
Be applied to or be sprayed on the affected part, twice of every day.
Illustrate:
1. the component ketoconazole among this side can be replaced with other antifungal agent (as clotrimazole, econazole and nystatin).
2. the component dimethyl sulfoxide among this side can be replaced with other skin penetrants such as azones.
3. the professional in field involved in the present invention can appropriateness increase and decrease each component of this side or its quantity under the situation of feature of the present invention according to the equal factor of administration object.
Claims (4)
1. the mixture of a pharmaceutical composition is characterized in that comprising antifungal agent and these two components of ethacridine are mixed for preparing treatment people and/or animal by the dermopathic medicine for external use due to the fungal infection.
2. claim 1 described antifungal agent refers to that at people's Canon Medicine and bright medicine and the pharmaceutical applications scope with antifungic action of animal pharmacopeia acceptance of the bid be treatment animal and/or human by the dermopathic topical drug due to the fungal infection.
3. claim 1 described medicine for external use can use all kinds of solvents, carrier and excipient to be mixed with various dosage forms as required.
4. the mixture of claim 1 described compositions can use jointly with other component when the preparation medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410058126 CN1626244A (en) | 2004-08-16 | 2004-08-16 | Combination for treating skin disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410058126 CN1626244A (en) | 2004-08-16 | 2004-08-16 | Combination for treating skin disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1626244A true CN1626244A (en) | 2005-06-15 |
Family
ID=34764265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410058126 Pending CN1626244A (en) | 2004-08-16 | 2004-08-16 | Combination for treating skin disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1626244A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104116747A (en) * | 2014-07-03 | 2014-10-29 | 李太玲 | Externally-applied medicine for treating dermatopathy caused by pathogenic fungi and preparation method thereof |
-
2004
- 2004-08-16 CN CN 200410058126 patent/CN1626244A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104116747A (en) * | 2014-07-03 | 2014-10-29 | 李太玲 | Externally-applied medicine for treating dermatopathy caused by pathogenic fungi and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1148186C (en) | Clonidine preparation | |
| CN1203864C (en) | Spray formulation of providone iodine | |
| CN1531430A (en) | Local used composition containing antifungal agent | |
| CN1035435A (en) | Be used for partial metronidazol preparation and treatment application thereof | |
| CN85109101A (en) | The preparation method of antibacterial ointment | |
| CN1205641A (en) | Administration media for analygesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compsns. containing such media and drugs | |
| CN1899291A (en) | External use antifungal compound composition and its use | |
| CN1154487C (en) | Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof | |
| CN1491108A (en) | Antifungal remedy formulation for external application | |
| CN1265838C (en) | Injectable veterinary composition for small animals | |
| CN1872279A (en) | Composition of medication for treating ulcer in the oral cavity, and preparation method | |
| CN1209972C (en) | Sterilization formulation and wet tissue, preparation method and use | |
| CN1316965C (en) | Transparent disappearing external administration carrier | |
| CN1883645A (en) | Composition for treating acne mainly | |
| CN1513530A (en) | Chinese medicine for treating ashen nail and its preparation method | |
| CN1626244A (en) | Combination for treating skin disease | |
| CN1732913A (en) | Propylgallate injection liquid with favorable stability and its preparation process | |
| CN1939539A (en) | Local prescription for wart, nail-disease treatment and nail care | |
| CN101053657A (en) | External applied preparations for treating intractable skin ulcer | |
| CN1925841A (en) | Pharmaceutical preparation for the oral cavity | |
| CN1748758A (en) | Dragon's blood gel preparation and its preparing method | |
| CN1084061A (en) | Agent for treating cataract and preparation method thereof | |
| CN1099285C (en) | Novel Anti-spasmodic composition and process for manufacture thereof | |
| CN1108532A (en) | Skin cancer treatment | |
| CN1593453A (en) | Sterilizing and bacteria inhibiting pharmaceutical composition and its formulation and preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |